American Association for Cancer Research
19406207capr150363-sup-156845_2_supp_3382183_g3djgy.docx (26.9 kB)

Supplementary Table 1 from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype

Download (26.9 kB)
journal contribution
posted on 2023-04-03, 22:08 authored by Priyanka Kanth, Mary P. Bronner, Kenneth M. Boucher, Randall W. Burt, Deborah W. Neklason, Curt H. Hagedorn, Don A. Delker

Patient Demographics


American College of Gastroenterology

University of Utah Personalized Medicine Program Seed


Cancer Center Support

National Center for Advancing Translational Sciences of the NIH

Huntsman Cancer Foundation



Sessile serrated colon adenoma/polyps (SSA/P) are found during routine screening colonoscopy and may account for 20% to 30% of colon cancers. However, differentiating SSA/Ps from hyperplastic polyps (HP) with little risk of cancer is challenging and complementary molecular markers are needed. In addition, the molecular mechanisms of colon cancer development from SSA/Ps are poorly understood. RNA sequencing (RNA-Seq) was performed on 21 SSA/Ps, 10 HPs, 10 adenomas, 21 uninvolved colon, and 20 control colon specimens. Differential expression and leave-one-out cross-validation methods were used to define a unique gene signature of SSA/Ps. Our SSA/P gene signature was evaluated in colon cancer RNA-Seq data from The Cancer Genome Atlas (TCGA) to identify a subtype of colon cancers that may develop from SSA/Ps. A total of 1,422 differentially expressed genes were found in SSA/Ps relative to controls. Serrated polyposis syndrome (n = 12) and sporadic SSA/Ps (n = 9) exhibited almost complete (96%) gene overlap. A 51-gene panel in SSA/P showed similar expression in a subset of TCGA colon cancers with high microsatellite instability. A smaller 7-gene panel showed high sensitivity and specificity in identifying BRAF-mutant, CpG island methylator phenotype high, and MLH1-silenced colon cancers. We describe a unique gene signature in SSA/Ps that identifies a subset of colon cancers likely to develop through the serrated pathway. These gene panels may be utilized for improved differentiation of SSA/Ps from HPs and provide insights into novel molecular pathways altered in colon cancer arising from the serrated pathway. Cancer Prev Res; 9(6); 456–65. ©2016 AACR.

Usage metrics

    Cancer Prevention Research



    Ref. manager